应对仿制药冲击与政治压力，诺和诺德Ozempic在美大幅降价

Core Viewpoint - Novo Nordisk has reduced the price of its diabetes drug Ozempic for cash-paying patients in the U.S. to $499 per month, less than half of the original price, amid increasing political pressure to lower drug prices [1][2]. Pricing Strategy - The original price of Ozempic for uninsured patients was approximately $1,350 per month, but the new price is set at $499 [1]. - Cash-paying patients can purchase Ozempic through various channels, including the drug's official website and Novo Nordisk's patient assistance program [1]. Competitive Landscape - Novo Nordisk's main competitor, Eli Lilly, has also lowered prices for its diabetes and weight loss medications for cash-paying patients [2]. - Wegovy, another product from Novo Nordisk, has seen its market share impacted by Eli Lilly's weight loss drug Zepbound, which has experienced a 199% year-over-year increase in weekly prescriptions, compared to Wegovy's 40% growth [2]. Generic Drug Competition - Novo Nordisk faces competition from generic versions of Wegovy and Ozempic produced by compounding pharmacies in the U.S. [3]. - The FDA has allowed the sale of these generics during periods of shortage, although Wegovy was removed from the FDA's shortage list earlier this year [3]. - Despite initial optimism about sales recovery, Novo Nordisk has indicated that approximately 1 million Americans are still using these non-branded formulations [3].